Mass Spectrometry-based Protein Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Signatures in Pancreatic Cancer - Biognosys

Mass Spectrometry-based Protein Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Signatures in Pancreatic Cancer

Poster presented at SITC 2022

Presenter: Nigel Beaton
In collaboration with the Parker Institute for Cancer Immunotherapy (PICI)

Back to Resources overview

Contact

    By submitting this form, you confirm that you consent to Biognosys processing of your personal data for the purposes and in the manner as described in our Privacy Notice.

    Close banner

    New: Spectronaut® 19

    Unlock Your Data's True Story

    New: Spectronaut® 19

    Unlock Your Data's True Story

    Learn More